{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigbngmcux3hns2z6aqyb57vzsh6bjlvlqi5qmpdwybbrn463xja3a",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mpp4kqxrjii2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreianaky5bsb6lwpdswrjzfvdtdisxa7igqpn2ithkqbg4yt6yblnim"
    },
    "mimeType": "image/jpeg",
    "size": 222233
  },
  "path": "/news/2026-07-fda-tzield-children-stage-diabetes.html",
  "publishedAt": "2026-07-02T17:40:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes.",
  "title": "FDA approves Tzield for children with new stage 3 type 1 diabetes"
}